Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

被引：1
|
作者：
Yuichi Terawaki
Chikayo Iwaya
Takashi Nomiyama
Dai Shimono
Tsuyoshi Horikawa
Yuki Fujimura-Tanaka
Toru Shigeoka
Nobuya Hamanoue
Ryoko Motonaga
Makito Tanabe
Toshihiko Yanase
Daiji Kawanami
机构：
[1] Fukuoka University,Department of Endocrinology and Diabetes Mellitus, School of Medicine
[2] Futata Tetsuhiro Clinic,undefined
[3] Muta Hospital,undefined
[4] Research Institute for Islet Biology,undefined
[5] Fukuoka University,undefined
来源：
Diabetology International | 2020年 / 11卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Insulin secretagogue; Glucose oscillation; Hypoglycemia; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：274 / 282
页数：8
相关论文
共 50 条
  • [1] Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)
    Terawaki, Yuichi
    Iwaya, Chikayo
    Nomiyama, Takashi
    Shimono, Dai
    Horikawa, Tsuyoshi
    Fujimura-Tanaka, Yuki
    Shigeoka, Toru
    Hamanoue, Nobuya
    Motonaga, Ryoko
    Tanabe, Makito
    Yanase, Toshihiko
    Kawanami, Daiji
    DIABETOLOGY INTERNATIONAL, 2020, 11 (03) : 274 - 282
  • [2] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    I. Raz
    M. Hanefeld
    L. Xu
    C. Caria
    D. Williams-Herman
    H. Khatami
    Diabetologia, 2006, 49 : 2564 - 2571
  • [3] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 (11) : 2564 - 2571
  • [4] Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus
    Yoneda, Chihiro
    Kobayashi, Junji
    Kuribayashi, Nobuichi
    DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 569 - 576
  • [5] Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
    Kadowaki, T.
    Kondo, K.
    DIABETES OBESITY & METABOLISM, 2013, 15 (09): : 810 - 818
  • [6] Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
    Iwamoto, Yasuhiko
    Taniguchi, Tadaaki
    Nonaka, Kenji
    Okamoto, Taro
    Okuyama, Kotoba
    Ferreira, Juan Camilo Arjona
    Amatruda, John
    ENDOCRINE JOURNAL, 2010, 57 (05) : 383 - 394
  • [7] EFFICACY AND SAFETY OF SAXAGLIPTIN, DIPEPTIDYL PEPTIDASE-4 INHIBITOR, IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, M.
    Otsuki, T.
    Maruyama, N.
    Oikawa, O.
    Okada, K.
    NEPHROLOGY, 2016, 21 : 65 - 65
  • [8] Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis
    Min, Se Hee
    Yoon, Jeong-Hwa
    Hahn, Seokyung
    Cho, Young Min
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (04) : 893 - 902
  • [9] Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Odawara M.
    Kadowaki T.
    Tajima N.
    Nishii M.
    Taniguchi T.
    Ferreira J.C.A.
    Diabetology International, 2011, 2 (2) : 94 - 105
  • [10] EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, Masanori
    Okada, Kazuyoshi
    Oikawa, Osamu
    Maruyama, Noriaki
    Furukawa, Tetsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 216 - 216
12345